PURPOSE: Patients with locally advanced head and neck cancer (LAHNC) undergo life-changing treatments that can seriously affect quality of life (QoL). This prospective study examined the key QoL domains during the first year after intensity-modulated radiotherapy (IMRT) and identified predictors of these changes in order to improve patient outcomes. PATIENTS AND METHODS: A consecutive series of patients with LAHNC completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core module (QLQ-C30) and the HNC-specific QLQ-HN35 before (t0) and at the end (t1) of definitive or adjuvant IMRT, then at 6-8 weeks (t2), 6 months (t3), and 1 year (t4) after IMRT. RESULTS: Patients (n = 111) completing questionnaires at all five time points were included (baseline response rate: 99%; dropout rate between t0 and t4: 5%). QoL deteriorated in all domains during IMRT and improved slowly during the first year thereafter. Many domains recovered to baseline values after 1 year but problems with smelling and tasting, dry mouth, and sticky saliva remained issues at this time. Increases in problems with sticky saliva were greater after 1 year in patients with definitive versus adjuvant IMRT (F = 3.5, P = 0.05). CONCLUSION: QoL in patients with LAHNC receiving IMRT takes approximately 1 year to return to baseline; some domains remain compromised after 1 year. Although IMRT aims to maintain function and QoL, patients experience long-term dry mouth and sticky saliva, particularly following definitive IMRT. Patients should be counseled at the start of therapy to reduce disappointment with the pace of recovery.
PURPOSE:Patients with locally advanced head and neck cancer (LAHNC) undergo life-changing treatments that can seriously affect quality of life (QoL). This prospective study examined the key QoL domains during the first year after intensity-modulated radiotherapy (IMRT) and identified predictors of these changes in order to improve patient outcomes. PATIENTS AND METHODS: A consecutive series of patients with LAHNC completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core module (QLQ-C30) and the HNC-specific QLQ-HN35 before (t0) and at the end (t1) of definitive or adjuvant IMRT, then at 6-8 weeks (t2), 6 months (t3), and 1 year (t4) after IMRT. RESULTS:Patients (n = 111) completing questionnaires at all five time points were included (baseline response rate: 99%; dropout rate between t0 and t4: 5%). QoL deteriorated in all domains during IMRT and improved slowly during the first year thereafter. Many domains recovered to baseline values after 1 year but problems with smelling and tasting, dry mouth, and sticky saliva remained issues at this time. Increases in problems with sticky saliva were greater after 1 year in patients with definitive versus adjuvant IMRT (F = 3.5, P = 0.05). CONCLUSION: QoL in patients with LAHNC receiving IMRT takes approximately 1 year to return to baseline; some domains remain compromised after 1 year. Although IMRT aims to maintain function and QoL, patients experience long-term dry mouth and sticky saliva, particularly following definitive IMRT. Patients should be counseled at the start of therapy to reduce disappointment with the pace of recovery.
Authors: K Bjordal; A de Graeff; P M Fayers; E Hammerlid; C van Pottelsberghe; D Curran; M Ahlner-Elmqvist; E J Maher; J W Meyza; A Brédart; A L Söderholm; J J Arraras; J S Feine; H Abendstein; R P Morton; T Pignon; P Huguenin; A Bottomly; S Kaasa Journal: Eur J Cancer Date: 2000-09 Impact factor: 9.162
Authors: Zoltán Nyárády; Arpád Németh; Agnes Bán; Adél Mukics; József Nyárády; István Ember; Lajos Olasz Journal: Anticancer Res Date: 2006 Mar-Apr Impact factor: 2.480
Authors: Mia Voordeckers; Hendrik Everaert; Koen Tournel; Dirk Verellen; Ilan Baron; Gretel Van Esch; Chris Vanhove; Guy Storme Journal: Strahlenther Onkol Date: 2008-08 Impact factor: 3.621
Authors: S Tribius; M S Meyer; C Pflug; H Hanken; C-J Busch; A Krüll; C Petersen; C Bergelt Journal: Strahlenther Onkol Date: 2018-05-07 Impact factor: 3.621
Authors: John V Hegde; Narek Shaverdian; Megan E Daly; Carol Felix; Deborah L Wong; Michael H Rosove; Jordan H Garst; Pin-Chieh Wang; Darlene Veruttipong; Shyam Rao; Ruben C Fragoso; Jonathan W Riess; Michael L Steinberg; Allen M Chen Journal: Cancer Date: 2017-10-17 Impact factor: 6.860
Authors: Andressa Silva de Freitas; Guilherme Maia Zica; Mariana Salles; Ana Catarina Alves E Silva; Thiago Huaytalla Silva; Fernando Luiz Dias; Izabella Costa Santos Journal: Int Arch Otorhinolaryngol Date: 2021-11-03
Authors: Hesham Elhalawani; Carlos E Cardenas; Stefania Volpe; Souptik Barua; Sonja Stieb; Calvin B Rock; Timothy Lin; Pei Yang; Haijun Wu; Jhankruti Zaveri; Baher Elgohari; Lamiaa E Abdallah; Amit Jethanandani; Abdallah S R Mohamed; Laurence E Court; Katherine A Hutcheson; G Brandon Gunn; David I Rosenthal; Steven J Frank; Adam S Garden; Arvind Rao; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2021-06-06